Bionomics receives A$1M milestone payment from Carina Biotech for BNC101
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2024
0mins
Should l Buy ?
Milestone Payment Received: Bionomics received a milestone payment of A$1M from Carina Biotech for the oncology program BNC101, under an exclusive licensing agreement signed in November 2020.
Future Financial Potential: Bionomics could earn up to A$118M in additional milestone payments and royalties from Carina Biotech's development and sales of therapies related to BNC101, which targets cancer stem cells.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
